By Fineline Cube 
US chip manufacturer NVIDIA (NASDAQ: NVDA) announced a strategic collaboration with Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) to enhance drug discovery processes through cutting-edge artificial intelligence (AI) applications. This partnership aligns with Novo Nordisk’s agreement with the Danish Center for AI (DCAI) to utilize the Gefion supercomputer, marking a significant step in integrating advanced AI technologies into pharmaceutical research.
Collaboration Details
The companies plan to develop customized AI models and agents for Novo Nordisk’s early-stage research and clinical development programs. This initiative will leverage NVIDIA’s advanced simulation and physics-informed AI technologies to streamline and accelerate the drug discovery process.
Technological Integration
DCAI’s Gefion supercomputer, powered by NVIDIA DGX SuperPOD, will serve as the AI factory for Novo Nordisk. The supercomputer will run drug discovery and AI agent workloads, utilizing NVIDIA BioNeMo for generative AI-driven drug discovery, NVIDIA NIM and NVIDIA NeMo microservices for customized agent workflows, and NVIDIA Omniverse to create simulation environments for physics-AI applications.
Research Focus
Novo Nordisk researchers will engage in multiple AI-driven projects, including the development of single-cell models to predict cellular responses to drug candidates and the design of models for constructing molecules with pharmaceutical properties. Additionally, the collaboration will focus on building biomedical large language models using Novo Nordisk’s extensive scientific literature database to uncover correlations between genes, proteins, and diseases.-Fineline Info & Tech